CGONCG Oncology, Inc.
$63.86+73% 1Y
$63.86
$36.4852 weeks$80.66
Is the business good?
How good a business is CGON?
CG Oncology, Inc. keeps −4056% of every revenue dollar as operating profit, against −77% for the median Biotechnology name.
−4056%
Operating margin · Biotechnology median −77% · 12 months to Q2 2026
- Share count, year on year
- +16%
Share count, year on year · shareholders own a smaller slice than a year ago
- R&D as % of revenue
- 2508%
R&D as % of revenue
| Year | Operating margin |
|---|---|
| FY2023 | −27181% |
| FY2024 | −10067% |
| FY2025 | −4722% |
Details›
- Operating margin12 months to Q2 2026
- −4056%
- Net margin12 months to Q2 2026
- −3603%
- Free cash flow margin
- −2880%
- R&D as % of revenue
- 2508%
- Revenue, trailing twelve months
- $6.2M
- Free cash flow, trailing twelve months
- −$179M
- Net income, trailing twelve months
- −$224M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
On our screens:Most shorted stocks
Biotechnology
The closest names by size in the same industry